Abstract 6417: LY3410738, a novel inhibitor of mutant IDH1 is more effective than Ivosidenib and potentiates antileukemic activity of standard chemotherapy in preclinical models of acute myeloid leukemia (AML)
Vivian Salama(The University of Texas MD Anderson Cancer Center), Marina Konopleva(Albert Einstein College of Medicine), Lisa Kays(Eli Lilly (United States)), Mary Sabatier(Inserm), P.L. Milligan(Eli Lilly (United States)), Jean‐Emmanuel Sarry(Inserm), Steven M. Chan(Princess Margaret Cancer Centre), Nathan A. Brooks(Eli Lilly (United States)), Kenneth D. Roth(Eli Lilly (United States)), K. David Newell(United States Geological Survey), Sandaruwan Geeganage(Eli Lilly (United States)), Anna Skwarska(Albert Einstein College of Medicine), Raymond Gilmour(Eli Lilly (Spain)), Courtney D. DiNardo(The University of Texas MD Anderson Cancer Center)
Cited by 8
Related Papers
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k